An observational study in MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Madrigal Pharmaceuticals, Inc.. Recruiting at 1 site in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Madrigal Pharmaceuticals, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.
Among the 212 studies in Fatty Liver with a site in United States, this one is the 43rd largest by planned enrollment of the 48 observational ones that give a count, is one of 15 that started in 2026, is one of 48 observational ones, reaches primary completion later than 42 of the 47 other live ones, and was the 200th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Kriya Therapeutics, Inc. · Sites in United States, New Zealand
Ages 18–75
Altimmune, Inc. · Sites in United States, Puerto Rico
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
212 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 57 · Phase 3 17 · Phase 4 12
First in 2001; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 150 across 207 observational studies indexed under Fatty Liver.
Median enrollment 44 across the 163 interventional studies, 85 across the 48 observational. Of the 149 that completed or were terminated, 63 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 212 have an industry lead sponsor. The 10 most frequent:
Madrigal Pharmaceuticals, Inc. is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Madrigal Pharmaceuticals, Inc. has 3 studies filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
14 of the studies in Fatty Liver with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06354088Columbia UniversityHuman Models of Selective Insulin Resistance: Alpelisib, Part I | 2026-12-31 |
| NCT04781322National Institute on Alcohol Abuse and Alcoholism (NIAAA)Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers | 2026-12-31 |
| NCT06944353Northwestern UniversityImproving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED | 2027-01 |
| NCT07491458Rivus Pharmaceuticals, Inc.A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) | 2027-02 |
| NCT07946341Cascade Pharmaceuticals, IncA Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380 | 2027-03-15 |
Add all 14 to your calendar (.ics) → With an account.
Among the 212 studies in Fatty Liver with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.
The purpose of the Rezdiffra™ Pregnancy and Lactation Registry is to create a worldwide information source, called a pregnancy registry. The registry will collect information about the safety of Rezdiffra™ (resmetirom), an approved medication, during pregnancy and/or while breastfeeding. This will help doctors and other healthcare providers learn more about its effect on pregnant and breastfeeding women and their infant after delivery up to 12 months of age.
The registry will allow healthcare providers (HCPs) to enroll eligible patients and will also allow eligible patients to self-enroll. The registry is voluntary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NONE
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Exposure to at least one dose of Resmetirom.
Pregnancy and Infant Outcomes Among Women Exposed to Rezdiffra During Pregnancy and/or Lactation
To evaluate pregnancy and infant outcomes among women with NASH exposed to Rezdiffra during pregnancy and/or lactation, including pregnancy outcomes, congenital malformations, and infant growth, development, and safety outcomes.
Time frame: From enrollment through pregnancy and up to 12 months of infant age (participant observational period up to approximately 21 months)
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Apr 2030, 49 months after the start.
Of 97 observational studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 49 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Madrigal Pharmaceuticals, Inc. →